ID

17575

Description

NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

Keywords

Versions (2)
  1. 9/11/16 9/11/16 -
  2. 9/25/16 9/25/16 -
Uploaded on

September 25, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC-ND 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

REFLECT-1 Visit 1 NCT00428090

English

REFLECT-1 Visit 1 NCT00428090

1 forms  
Patient Information
Description

Patient Information

Alias
UMLS CUI-1
C1955348
Patient ID
Description

Patient Study ID

Data type

text

Alias
UMLS CUI [1]
C2348585
Visit Date
Description

Visit Date

Data type

date

Measurement units
  • dd/MMM/yy
Alias
UMLS CUI [1]
C1320303
dd/MMM/yy
Previous Clinical Trial Participation
Description

Previous Clinical Trial Participation

Alias
UMLS CUI-1
C2348568
Did the subject participate in AVA 100 clinical study 193?
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
If "Yes", complete the following: Previous Centre ID
Description

Previous Centre ID

Data type

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0019994
UMLS CUI [1,3]
C0205156
If "Yes", complete the following: Previous Subject Identifie
Description

Previous Patient Study ID

Data type

text

Alias
UMLS CUI [1,1]
C2348585
UMLS CUI [1,2]
C0205156
Eligibility Question
Description

Eligibility Question

Alias
UMLS CUI-1
C1516637
Did the subject meet all the entry criteria? (If "No", tick all boxes corresponding to violations of any inclusion/exclusion criteria. Do NOT enter the subject into the study if they failed any inclusion or exclusion criteria below.)
Description

Eligibility Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1516637
Inclusion Criteria - tick all boxes corresponding to any of any of the inclusion criteria the subject failed.
Description

Inclusion Criteria - tick all boxes corresponding to any of any of the inclusion criteria the subject failed.

Alias
UMLS CUI-1
C1512693
1. Male or female subject who has successfully completed Visit 8 of AVA 100193 (24 weeks of treatment) without tolerability issues, where in the opinion of the subject and of the investigator, it will be beneficial to continue treatment with RSG XR.
Description

Completion of previous study and treatment with RSG XR

Data type

boolean

Alias
UMLS CUI [1]
C2732579
UMLS CUI [2,1]
C0289313
UMLS CUI [2,2]
C0013216
2. Female subjects must be post-menopausal (i.e. > 6 months without menstrual period), surgically sterile, or if of child-bearing potential, using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures throughout the study and for 30 days after discontinuing study medication. The subject and their caregiver must ensure that the subject will continously use contraceptive measures throughout the duration of the study.
Description

Gynaecological status

Data type

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0015787
UMLS CUI [3]
C0700589
3. Subject is willing to participate in the extention study and has provided full wirtten informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full wirtten informed consent on behalf of the subject has been provided by a legally acceptable representative.
Description

Informed Consent: Study Participation and Cognitive Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C2348568
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0945985
4. Caregiver has provided full written informed consent on his or her won behalf prior to the performance of any protocol-specified procedure.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria - tick the boxes corresponding to any of the exclusion criteria that disqualified the subject from entry.
Description

Exclusion Criteria - tick the boxes corresponding to any of the exclusion criteria that disqualified the subject from entry.

Alias
UMLS CUI-1
C0680251
1. Subject had a serious adverse experience or clinically significant laboratory abnormality during AVA100193, which in the opinion of the investigator could have been attributable to study medication, and which is ongoing at the end of AVA100193.
Description

Adverse Event or laboratory abnormality due to study drug

Data type

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0304229
UMLS CUI [2,1]
C0438215
UMLS CUI [2,2]
C0304229
2. The subject is felt by the investigator to be unsuitable (on the basis of health, compliance, caregiver availability, or for any other reason) for inclusion in the study.
Description

Health status, Compliance, Caregiver availability, Other reason

Data type

boolean

Alias
UMLS CUI [1]
C0018759
UMLS CUI [2]
C1321605
UMLS CUI [3,1]
C0470187
UMLS CUI [3,2]
C0085537
UMLS CUI [4]
C3840932
3. The subject experienced a significant cardiovascular event during AVA100193 (e.g. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome (on Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or significant arrhythmia), unless a thorough cardiovascular evaluation has been performed which confirms that the subject does not have congestive heart failure, and is clinically stable
Description

Cardiovascular status

Data type

boolean

Alias
UMLS CUI [1]
C0007222
4. Treatment with a cholinesterase inhibitor, selegiline, memantine or any other treatment for cognitive symptoms/AD (including but not limited to papaverin, cinnarisin, cerebrolysin) is initiated at the end of AVA100193.
Description

Concomitant medication

Data type

boolean

Alias
UMLS CUI [1]
C2347852
Investiagional Product - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).
Description

Investiagional Product - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).

Alias
UMLS CUI-1
C0304229
Investigational Product (e.g Bottle 1)
Description

Investigational Product

Data type

text

Alias
UMLS CUI [1]
C0304229
Start Date
Description

Start Date

Data type

date

Measurement units
  • dd/MMM/yy
Alias
UMLS CUI [1]
C0808070
dd/MMM/yy
Stop Date
Description

Stop Date

Data type

date

Measurement units
  • dd/MMM/yy
Alias
UMLS CUI [1]
C0806020
dd/MMM/yy
Dose
Description

Dose

Data type

float

Measurement units
  • mg
Alias
UMLS CUI [1]
C3174092
mg
IP Container No.
Description

IP Container No.

Data type

float

Alias
UMLS CUI [1]
C0180098
Has the subject missed investigational product for > 7 consecutive days?
Description

Discontinuation

Data type

boolean

Alias
UMLS CUI [1]
C0457454
Compliance - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).
Description

Compliance - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).

Alias
UMLS CUI-1
C1321605
Total number of Tablets Dispensed
Description

Total number of Tablets Dispensed

Data type

float

Alias
UMLS CUI [1,1]
C0805077
UMLS CUI [1,2]
C0039225
Total number of Tablets Returned
Description

Total number of Tablets Returned

Data type

float

Alias
UMLS CUI [1,1]
C2699071
UMLS CUI [1,2]
C0039225
End of Visit Reminder
Description

End of Visit Reminder

Alias
UMLS CUI-1
C1709896
UMLS CUI-2
C1320303
Schedule Visit 2 for 14 days (+- 3 days) after this visit. It is not necessary for the subject to be fasted.
Description

End of Visit Reminder

Data type

text

Alias
UMLS CUI [1,1]
C1709896
UMLS CUI [1,2]
C1320303
Back to the top of the page

Similar models

REFLECT-1 Visit 1 NCT00428090

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Patient Information
C1955348 (UMLS CUI-1)
Patient Study ID
Item
Patient ID
text
C2348585 (UMLS CUI [1])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
Item Group
Previous Clinical Trial Participation
C2348568 (UMLS CUI-1)
Study Subject Participation Status
Item
Did the subject participate in AVA 100 clinical study 193?
boolean
C2348568 (UMLS CUI [1])
Previous Centre ID
Item
If "Yes", complete the following: Previous Centre ID
text
C0600091 (UMLS CUI [1,1])
C0019994 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Previous Patient Study ID
Item
If "Yes", complete the following: Previous Subject Identifie
text
C2348585 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Item Group
Eligibility Question
C1516637 (UMLS CUI-1)
Eligibility Criteria
Item
Did the subject meet all the entry criteria? (If "No", tick all boxes corresponding to violations of any inclusion/exclusion criteria. Do NOT enter the subject into the study if they failed any inclusion or exclusion criteria below.)
boolean
C1516637 (UMLS CUI [1])
Item Group
Inclusion Criteria - tick all boxes corresponding to any of any of the inclusion criteria the subject failed.
C1512693 (UMLS CUI-1)
Completion of previous study and treatment with RSG XR
Item
1. Male or female subject who has successfully completed Visit 8 of AVA 100193 (24 weeks of treatment) without tolerability issues, where in the opinion of the subject and of the investigator, it will be beneficial to continue treatment with RSG XR.
boolean
C2732579 (UMLS CUI [1])
C0289313 (UMLS CUI [2,1])
C0013216 (UMLS CUI [2,2])
Gynaecological status
Item
2. Female subjects must be post-menopausal (i.e. > 6 months without menstrual period), surgically sterile, or if of child-bearing potential, using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures throughout the study and for 30 days after discontinuing study medication. The subject and their caregiver must ensure that the subject will continously use contraceptive measures throughout the duration of the study.
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Informed Consent: Study Participation and Cognitive Status
Item
3. Subject is willing to participate in the extention study and has provided full wirtten informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full wirtten informed consent on behalf of the subject has been provided by a legally acceptable representative.
boolean
C0021430 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0945985 (UMLS CUI [2,2])
Informed Consent
Item
4. Caregiver has provided full written informed consent on his or her won behalf prior to the performance of any protocol-specified procedure.
boolean
C0021430 (UMLS CUI [1])
Item Group
Exclusion Criteria - tick the boxes corresponding to any of the exclusion criteria that disqualified the subject from entry.
C0680251 (UMLS CUI-1)
Adverse Event or laboratory abnormality due to study drug
Item
1. Subject had a serious adverse experience or clinically significant laboratory abnormality during AVA100193, which in the opinion of the investigator could have been attributable to study medication, and which is ongoing at the end of AVA100193.
boolean
C0877248 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0438215 (UMLS CUI [2,1])
C0304229 (UMLS CUI [2,2])
Health status, Compliance, Caregiver availability, Other reason
Item
2. The subject is felt by the investigator to be unsuitable (on the basis of health, compliance, caregiver availability, or for any other reason) for inclusion in the study.
boolean
C0018759 (UMLS CUI [1])
C1321605 (UMLS CUI [2])
C0470187 (UMLS CUI [3,1])
C0085537 (UMLS CUI [3,2])
C3840932 (UMLS CUI [4])
Cardiovascular status
Item
3. The subject experienced a significant cardiovascular event during AVA100193 (e.g. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome (on Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or significant arrhythmia), unless a thorough cardiovascular evaluation has been performed which confirms that the subject does not have congestive heart failure, and is clinically stable
boolean
C0007222 (UMLS CUI [1])
Concomitant medication
Item
4. Treatment with a cholinesterase inhibitor, selegiline, memantine or any other treatment for cognitive symptoms/AD (including but not limited to papaverin, cinnarisin, cerebrolysin) is initiated at the end of AVA100193.
boolean
C2347852 (UMLS CUI [1])
Item Group
Investiagional Product - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).
C0304229 (UMLS CUI-1)
Investigational Product
Item
Investigational Product (e.g Bottle 1)
text
C0304229 (UMLS CUI [1])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Stop Date
Item
Stop Date
date
C0806020 (UMLS CUI [1])
Dose
Item
Dose
float
C3174092 (UMLS CUI [1])
IP Container No.
Item
IP Container No.
float
C0180098 (UMLS CUI [1])
Discontinuation
Item
Has the subject missed investigational product for > 7 consecutive days?
boolean
C0457454 (UMLS CUI [1])
Item Group
Compliance - dispense the first bottle of study medication (Weeks 1 - 4) as specified by the IVRS system . Record start date, container number and number of tablets dispensed below (stop date and tablets returned will be completed when the bottle is returned at Visit 3).
C1321605 (UMLS CUI-1)
Total number of Tablets Dispensed
Item
Total number of Tablets Dispensed
float
C0805077 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
Total number of Tablets Returned
Item
Total number of Tablets Returned
float
C2699071 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
Item Group
End of Visit Reminder
C1709896 (UMLS CUI-1)
C1320303 (UMLS CUI-2)
End of Visit Reminder
Item
Schedule Visit 2 for 14 days (+- 3 days) after this visit. It is not necessary for the subject to be fasted.
text
C1709896 (UMLS CUI [1,1])
C1320303 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial